Strategi monitoring kepatuhan penggunaan antiretroviral pre-exposure prophilaxis pada pasangan serodiscordant

https://doi.org/10.22146/bkm.35359

Ni Kadek Diah Purnamayanti(1*), Nurma Yuni Pari Usemahu(2), Fatih Haris M(3), Marina Kristi Layun R(4)

(1) Magister Keperawatan, Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada
(2) Magister Keperawatan, Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada
(3) Magister Keperawatan, Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada
(4) Magister Keperawatan, Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan Universitas Gadjah Mada
(*) Corresponding Author

Abstract


Monitoring strategy of antiretroviral pre-exposure prophylaxis adherence among serodiscordant couple  

Antiretroviral pre-exposure prophylaxis (PrEP) has been recommended as HIV prevention but poor medical adherence can cause suboptimal therapy. This study explored the strategies of monitoring PrEP adherence among the serodiscordant couples. This systematic review based on 4 data bases (Scopus, Pubmed, Ebsco and Sage Journal), included clinical trial studies articles between 2013-2018, in English, and available in full-text. Papers, which not met the inclusion criteria, will be excluded. Keywords used in this study are ‘serodiscordant couple’ AND ‘method’ OR ‘strategy’ OR ‘approach’ AND ‘pre-exposure prophylaxis intention’ OR ‘pre-exposure prophylaxis adherence’. This study discovered various strategies applied based on the type of delivering process, the variance of dose, and variance of preference of the couple. Preference of PrEP dose and type of application related to heterosexual or homosexual orientation and their social commitment. The paper explains the advantage of M-health and biomarker level monitoring. 


Keywords


adherence; pre-exposure prophylaxis; serodiscordant couple

Full Text:

PDF


References

  1. Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HGM, Dodoo ANO. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf. 2017;40(4):273–83.
  2. Couples FORS. Guidance on Pre-Exposure Oral Prophilaxis (PrEP) for Sediscordant Couples and Transgender Who have Sex with Man at High Risk of HIV July 2012. Leonardo. 2012;(July):106–106.
  3. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 Clinical Practice Guideline. Mmwr. 2014;1–67.
  4. Elsasser J. April 2012. Public Relations Tactics. 2012;19(4):3.
  5. Dima AL, Schweitzer AM, Amico KR, Wanless RS. The Information-Motivation-Behavioral Skills Model of ART Adherence in Romanian Young Adults. J HIV/AIDS Soc Serv. 2013;12(3–4):274–93.
  6. Russell C. An overview of the integrative research review. Prog Transplant [Internet]. 2005;15(1):8–13. Available from: http://progressintransplantation.com/doi/abs/10.7182/prtr.15.1.0n13660r26g725kj
  7. Crowe M. CCAT form v1.4. 2013;4(November):4–5.
  8. Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials [Internet]. 2009;4(2):79–88. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2694951&tool=pmcentrez&rendertype=abstract
  9. PRISMA Statement. PRISMA Flowchart Diagram [Internet]. 2015 [cited 2018 May 9]. Available from: http://prisma-statement.org/prismastatement/flowdiagram.aspx
  10. Murnane PM, Brown ER, Donnell D, Coley RY, Mugo N, Mujugira A, et al. Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. Am J Epidemiol. 2015;182(10):848–56.
  11. Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu CS, et al. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One. 2017;12(7):1–17.
  12. Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. PLoS One. 2013;8(9):1–10.
  13. Mayer KH, Safren SA, Elsesser SA, Psaros C, Tinsley JP, Marzinke M, et al. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of “Life-Steps for PrEP.” AIDS Behav. 2017;21(5):1350–60.
  14. Shrestha R, Altice FL, Karki P, Copenhaver MM. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study. AIDS Behav. 2018;(123456789):1–10.
  15. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 Vaginal microbicides trial using a mixed methods and triangulation model. PLoS One. 2010;5(7).



DOI: https://doi.org/10.22146/bkm.35359

Article Metrics

Abstract views : 3409 | views : 3147

Refbacks

  • There are currently no refbacks.




Copyright (c) 2019 Berita Kedokteran Masyarakat

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Berita Kedokteran Masyarakat ISSN 0215-1936 (PRINT), ISSN: 2614-8412 (ONLINE).

Indexed by:


Web
Analytics Visitor Counter